Phoenix, AZNCT07008118Now EnrollingIRB Ready

Myeloproliferative Neoplasms Clinical Trial in Phoenix, AZ

Access cutting-edge myeloproliferative neoplasms treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.

Sponsored by Incyte Corporation

Quick Self-Assessment

See if you qualify for this Phoenix location

Preparing your pre-screening questions…

Expert Care in Phoenix

Access myeloproliferative neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myeloproliferative neoplasms treatment provided free

Apply for This Phoenix Location

Check if you qualify for this myeloproliferative neoplasms clinical trial in Phoenix, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Phoenix

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Phoenix site if eligible
  4. 4Begin participation

About This Myeloproliferative Neoplasms Study in Phoenix

This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.

Sponsor: Incyte Corporation

Who Can Participate

Inclusion Criteria

Age 18 years or older at the time of signing the ICF
ECOG performance status of 0 to 1 for the dose escalation (Part 1a) and 0 to 2 for the dose expansion (Part 1b)
Documented CALR exon-9 mutation
Confirmed diagnosis of MPN according to the 2022 ICC criteria:
DIPSS+ intermediate-2/high-risk MF with prior JAKi, \<20% blasts, and measurable spleen
High-risk ET with platelets \>450×10⁹/L
Resistant, refractory, intolerant, or has lost response to ≥1 prior line of therapy for MF and ≥2 prior lines for ET (unless only a single standard-of-care option is approved in the participating country)
No prior stem cell transplant and none planned within 6 months
Minimum Laboratory Requirements:
Platelet count ≥50 × 10⁹/L
Absolute neutrophil count ≥1 × 10⁹/L
International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤1.5 × upper limit of normal (ULN), unless receiving vitamin K antagonists
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<2.5 × ULN
Total bilirubin \<2 × ULN
Estimated creatinine clearance \>45 or \>30 mL/min (depending on study part)

Exclusion Criteria

Major bleeding or thrombosis (e.g., stroke, DVT, PE) within the past 3 months
Active or high-risk HBV, HCV, or HIV infection, or other chronic active infections requiring systemic treatment
Active invasive cancer within the past 2 years, except certain early-stage or low-risk cancers (e.g., resected skin, cervical, thyroid, or prostate cancer)
Pregnant or unwilling to avoid pregnancy or fathering a child during the study and for a defined period after the last dose. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Phoenix?

Yes, this clinical trial (NCT07008118) has an active research site in Phoenix, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myeloproliferative Neoplasms Treatment Options in Phoenix, AZ

If you're searching for myeloproliferative neoplasms treatment options in Phoenix, AZ, this clinical trial (NCT07008118) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myeloproliferative neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myeloproliferative neoplasms clinical trials near you to find additional studies recruiting in your area.

More Myeloproliferative Neoplasms Trials in Phoenix, AZ

See all myeloproliferative neoplasms clinical trials recruiting in Phoenix — not just this study.

Browse Myeloproliferative Neoplasms Trials in Phoenix →

Browse More Trials by Condition

Myeloproliferative Neoplasms TrialsMultiple Sclerosis TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Phoenix?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Phoenix, AZ